Mark Sydenham

8.2k citations

42 papers · 3.3k indexed · 2 hit papers · h-index 16

Otorhinolaryngology top 0.2%
- Head and Neck Cancer Studies 10
Radiation top 0.5%
- Advanced Radiotherapy Techniques 5
Cancer Research top 1%
- Breast Cancer Treatment Studies 19
Radiology, Nuclear Medicine and Imaging top 2%
- Advances in Oncology and Radiotherapy 5
Oncology top 5%
- Global Cancer Incidence and Screening 5
Molecular Biology
- Viral Infectious Diseases and Gene Expression in Insects 7
- Insect Resistance and Genetics 4
Surgery
- Salivary Gland Tumors Diagnosis and Treatment 5

Co-authors: Martin Pagé John Yarnold Joanne Haviland Judith M. Bliss James P. Morden Roger A’Hern Emma Hall F. Adab
Cited by: Otorhinolaryngology Radiation Cancer Research
Journals: Radiotherapy and Oncology (9 papers)Journal of Clinical Oncology (6 papers)Clinical Oncology (5 papers)
Partner nations: United Kingdom Canada United States

In The Last Decade

Mark Sydenham

37 papers receiving 3.2k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Mark Sydenham

Since Specialization

Citations

This map shows the geographic impact of Mark Sydenham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sydenham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sydenham more than expected).

Fields of papers citing papers by Mark Sydenham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Sydenham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sydenham. The network helps show where Mark Sydenham may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark Sydenham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Sydenham Line = papers co-authored together Mark Sydenham links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial The Lancet Oncology ·Anna M. Kirby,Laura Finneran,Clare Griffin,Adrian Murray Brunt,Fay Cafferty,Abdulla Alhasso,Charlie Chan,Joanne Haviland,Monica Jefford,Elinor J. Sawyer,Mark Sydenham,Isabel Syndikus,Y. Tsang,Duncan Wheatley,John Yarnold,Charlotte E. Coles,Judith M. Bliss	2025	0
2	Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial Radiotherapy and Oncology ·Jan Joosten,Lucy Kilburn,Anna M. Kirby,Clare Griffin,Mark Sydenham,Cliona Kirwan,Joanne Haviland,Indrani Bhattacharya,Monica Jefford,Isabel Syndikus,Judith M. Bliss,Charlotte E. Coles	2025	1
3	Baseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5 years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trials Radiotherapy and Oncology ·Jan Joosten,Anna M. Kirby,Lucy Kilburn,Clare Griffin,Mark Sydenham,刁鹏飞,Cliona Kirwan,Monica Jefford,Isabel Syndikus,Judith M. Bliss,Charlotte E. Coles	2025	0
4	Regional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer Radiotherapy Clinical Oncology ·Zohal Nabi,M. E. Ortiz-Romero-Vargas,Patricia Díez,Abdullah Rathur,Rashid Mir,Duncan Wheatley,Ghajar-KhosraviShadi,Judith M. Bliss,Joanne Haviland,Mark Sydenham,Emiliano Spezi,Y. Tsang,Adrian Murray Brunt	2025	0
5	Abstract PO5-22-04: Genomic analysis of local recurrences following risk adapted breast radiotherapy in the IMPORT trials defines 'true recurrences' and 'new primaries' Cancer Research ·Sara Lightowlers,E. Braun,Elena Provenzano,Judith M. Bliss,Jason S. Carroll,Hui Pana,Clare Griffin,Joanne Haviland,Monica Jefford,Anna M. Kirby,Navita Somaiah,Mark Sydenham,Jenny Titley,John Yarnold,Charlotte E. Coles,Elinor J. Sawyer	2024	1
6	Partial Breast Radiotherapy for Women with Early Breast Cancer: 10-Year Outcomes from IMPORT LOW (CRUK/06/003) International Journal of Radiation OncologyBiologyPhysics ·Anna M. Kirby,Clare Griffin,Laura Finneran,Mark Sydenham,Abdulla Alhasso,Adrian Murray Brunt,Hsiao Yun Chan,Monica Jefford,Jerome M Jamilo,Isabel Syndikus,Y. Tsang,Duncan Wheatley,John Yarnold,Charlotte E. Coles,Judith M. Bliss	2023	0
7	Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials Radiotherapy and Oncology ·Joanne Haviland,Mariella Mannino,Clare Griffin,Núria Porta,Mark Sydenham,Judith M. Bliss,John Yarnold	2017	55
8	Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial Radiotherapy and Oncology ·Adrian Murray Brunt,Duncan Wheatley,John Yarnold,Navita Somaiah,Stephen Kelly,Adrian Harnett,Charlotte E. Coles,Andrew Goodman,Amit Bahl,Mark Churn,Clement Obuene,Mark Sydenham,Clare Griffin,James P. Morden,Judith M. Bliss	2016	149
9	Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer Clinical Oncology ·Joanne Haviland,Penelope Hopwood,J. Mills,Mark Sydenham,Judith M. Bliss,John Yarnold	2016	22
10	Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy Radiation Oncology ·Charlotte Westbury,Joanne Haviland,Sue Davies,Lone Gothard,Yudhi satria Restu,Mark Sydenham,Jo Bowen,Richard Stratton,Susan Short,John Yarnold	2014	13
11	The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trialsbreakdown → The Lancet Oncology ·Joanne Haviland,John R. Owen,John Dewar,R. K. Agrawal,Jane Barrett,Peter Barrett‐Lee,H.J. Dobbs,Penelope Hopwood,P.A. Lawton,Brian Magee,Judith Mills,Sandra F. Simmons,Mark Sydenham,Karen Venables,Judith M. Bliss,John Yarnold	2013	940
12	Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trialbreakdown → The Lancet Oncology ·Christopher M. Nutting,James P. Morden,Kevin J. Harrington,Teresa Guerrero Urbano,Shreerang Bhide,Catharine H. Clark,Elizabeth Miles,Aisha Miah,Kate Newbold,Mary Anne Tanay,F. Adab,Sarah Jefferies,Christopher Scrase,B. Yap,Roger A’Hern,Mark Sydenham,Marie A. Emson,Emma Hall	2011	1202
13	Large breast size as a risk factor for late adverse effects of breast radiotherapy: Is residual dose inhomogeneity, despite 3D treatment planning and delivery, the main explanation? Radiotherapy and Oncology ·Kiran Kamal Prasad,Joanne Haviland,Y. Tsang,Mark Sydenham,John Yarnold	2011	60
14	Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapy Radiotherapy and Oncology ·Susan Martin,Mark Sydenham,Joanne Haviland,Roger A’Hern,Roger Owen,Judith M. Bliss,John Yarnold	2010	12
15	First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005) Journal of Clinical Oncology ·C. Nutting,Roger A’Hern,Zhang Maolin,Mark Sydenham,F. Adab,Kevin J. Harrington,S. Jefferies,Christopher Scrase,B. Yap,Emma Hall	2009	9
16	Evaluation of a Method for Grading Late Photographic Change in Breast Appearance after Radiotherapy for Early Breast Cancer Clinical Oncology ·Joanne Haviland,Anita Ashton,P Viorel,Lone Gothard,John R. Owen,Diana Tait,Mark Sydenham,John Yarnold,Judith M. Bliss	2008	23
17	Hypofractionation for early breast cancer: First results of the UK standardization of breast radiotherapy (START) trials Journal of Clinical Oncology ·J A Dewar,Joanne Haviland,R. K. Agrawal,Judith M. Bliss,Penelope Hopwood,B. Magee,John R. Owen,Mark Sydenham,Karen Venables,John Yarnold	2007	12
18	Enhanced expression of recombinant proteins in insect cells using a baculovirus vector containing a bacterial leader sequence Nucleic Acids Research ·Timothy C. Peakman,Dainius Amerigas Piscikas,Mark Sydenham,Dirk R. Gewert,Martin Pagé,Andrew Makoff	1992	9
19	Expression of the mouse c-abl type IV proto-oncogene product in the insect cell baculovirus system Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Timothy C. Peakman,Charles H. Reynolds,村山美佐緒,Jonathan D. Moore,Paul Spence,Mark Sydenham,D. Linstead,Dirk R. Gewert,Martin Pagé	1992	2
20	Functional properties of human thyroid hormone receptor β1 overexpressed using baculovirus FEBS Letters ·Trevor N. Collingwood,Mark Sydenham,Martin Pagé,Krishna Chatterjee	1991	5

About Mark Sydenham

Mark Sydenham is a scholar working on Otorhinolaryngology, Cancer Research and Radiation, having authored 42 papers that have together received 3.3k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (19 papers), Head and Neck Cancer Studies (10 papers), Viral Infectious Diseases and Gene Expression in Insects (7 papers), Global Cancer Incidence and Screening (5 papers), Advanced Radiotherapy Techniques (5 papers), Advances in Oncology and Radiotherapy (5 papers), Salivary Gland Tumors Diagnosis and Treatment (5 papers) and Insect Resistance and Genetics (4 papers). The work is most often cited by research in Otorhinolaryngology (1.1k citations), Radiation (878 citations) and Cancer Research (1.1k citations). Mark Sydenham has collaborated with scholars based in United Kingdom, Canada and United States. Frequent co-authors include Martin Pagé, John Yarnold, Joanne Haviland, Judith M. Bliss, James P. Morden, Roger A’Hern, Emma Hall, F. Adab, B. Yap and Kevin J. Harrington. Their work appears in journals such as Radiotherapy and Oncology, Journal of Clinical Oncology, Clinical Oncology, The Lancet Oncology and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact